The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index; none of the 5 sources its claims cite is checked for support yet.
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Own result · 2 Not checked yet · 2 Own method · 2 Own interpretation
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cancer history represented the highest risk for severe events (appendix p 3).”
plaincorrelationaln = 18 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“patients with cancer were observed to have a higher risk of severe events (a composite endpoint defined as the percentage of patients being admitted to the intensive care unit requiring invasive ventilation, or death) compared with patients without cancer (seven [39%] of 18 patients vs 124 [8%] of 1572 patients; Fisher's exact p=0·0003).”
plaincorrelationaln = 18 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients with lung cancer did not have a higher probability of severe events compared with patients with other cancer types (one [20%] of five patients with lung cancer vs eight [62%] of 13 patients with other types of cancer; p=0·294).”
plainn = 13- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“more likely to have a history of smoking (four [22%] of 18 patients vs 107 [7%] of 1572 patients)”
plaincorrelationaln = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“had more polypnea (eight [47%] of 17 patients vs 323 [23%] of 1377 patients; some data were missing on polypnea)”
plaincorrelationaln = 17- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“18 (1%; 95% CI 0·61–1·65) of 1590 COVID-19 cases had a history of cancer”
plainn = 1,590- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed similar results when the severe events were defined both by the above objective events and physician evaluation (nine [50%] of 18 patients vs 245 [16%] of 1572 patients; Fisher's exact p=0·0008).”
plaincorrelationaln = 18 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“patients with cancer deteriorated more rapidly than those without cancer (median time to severe events 13 days [IQR 6–15] vs 43 days [20–not reached]; p<0·0001; hazard ratio 3·56, 95% CI 1·65–7·69, after adjusting for age; figure).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with cancer, older age was the only risk factor for severe events (OR 1·43, 95% CI 0·97–2·12; p=0·072).”
plaincorrelationaln = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared with patients without cancer, patients with cancer were older (mean age 63·1 years [SD 12·1] vs 48·7 years [16·2])”
plaincorrelationaln = 1,590- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 3
- Probably not a substantial claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but had no significant differences in sex, other baseline symptoms, other comorbidities, or baseline severity of x-ray (appendix p 2).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Four (25%) of 16 patients (two of the 18 patients had unknown treatment status) with cancer with COVID-19 had received chemotherapy or surgery within the past month, and the other 12 (25%) patients were cancer survivors in routine follow-up after primary resection.”
plainn = 16- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We excluded 417 cases because of insufficient records of previous disease history.”
plainn = 417- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All cases were diagnosed with laboratory-confirmed COVID-19 acute respiratory disease and were admitted to hospital.”
plainn = 2,007- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The 2015 cancer incidence in the overall Chinese population is a valid comparator for the proportion of cancer history among COVID-19 cases in the 2020 cohort.
“which seems to be higher than the incidence of cancer in the overall Chinese population (285·83 [0·29%] per 100 000 people, according to 2015 cancer epidemiology statistics9)”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Survivors presenting with COVID-19 face a higher risk of being admitted to an ICU, being placed on a ventilator, or dying compared to noncancer patients with COVID-19.6”
From Cancer during a pandemic: A psychosocial telehealth intervention for young adults (2022) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Self-isolation was extremely important, especially for cancer patients, as they are a group at higher risk of death or complications due to their systemic immunosuppressive state caused by the disease and its drug treatment [27].”
From The Effect of Vinyasa Yoga Practice on the Well-Being of Breast-Cancer Patients during COVID-19 Pandemic (2023) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Older adults diagnosed with both cancer and COVID-19 face increased mortality, hospitalization, and ICU admission [3,4,5].”
From The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is particularly true of older adults with cancer, who may be among the most vulnerable to the effects of COVID-19 due to their immunocompromised status and increased presence of comorbidities [1,2,3,4,5].”
From The Psychosocial Impact of COVID-19 on Older Adults with Cancer: A Rapid Review (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Due to the high risk for contracting and suffering complications of COVID-19 among oncology patients, prevention of acute healthcare utilization, such as emergency room (ER) visits and hospitalizations, is increasingly important during the COVID-19 pandemic [1, 2].”
From Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic (2021) · cites this paper as [1]
In the citing paper
“While the virus affects people of all ages, data have consistently shown that mortality is higher with increasing age and comorbidities [[3], [4], [5], [6]].”
In the citing paper
“Patients with cancer have higher risk of being admitted to intensive care unit requiring invasive ventilators or dying from COVID-19 than patients without cancer due to their systemic immunosuppressive state induced by the disease and its pharmacological treatments [5].”
From Physical activity for cancer patients during COVID-19 pandemic: A call to action (2021) · cites this paper as [5]
In the citing paper
“Current available information suggests that people age 65+, those with underlying medical conditions such as lung disease, people with weakened immune systems, and people undergoing cancer treatment may be at increased risk for severe illness from the novel coronavirus (COVID-19). 1,2”
From Behavioral and psychosocial responses of people receiving treatment for advanced lung cancer during the COVID‐19 pandemic: A qualitative analysis (2020) · cites this paper as [2]
In the citing paper
“SARS-CoV-2 infections in patients with cancer appear more likely to cause severe morbidity and mortality, owing in part to these individuals' more advanced age and in part to the immunosuppressive effects of their malignancies and the drugs, radiation, and surgical procedures used to treat them (10–12).”
From Cancer Care During COVID-19 Era: The Quality of Life of Patients With Thyroid Malignancies (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Four (25%) of 16 patients (two of the 18 patients had unknown treatment status) with cancer with COVID-19 had received chemotherapy or surgery within the past month, and the other 12 (25%) patients were cancer survivors in routine follow-up after primary resection.”
Reported 25 · recomputed 75
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
“two of the 18 patients had unknown treatment status”
§ Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
“three [75%] of four patients) of clinically severe events than did those not receiving chemotherapy or surgery (six [43%] of 14 patients”
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
A novel coronavirus outbreak of global health concern
Wang, C., Horby, P. W., Hayden, F. G., & Gao, G. F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30185-9 · Cited by 7,700
Hamming, I., Timens, W., Bulthuis, M., Lely, A., Navis, G., & van Goor, H. (2004) · The Journal of Pathology · doi:10.1002/path.1570 · Cited by 5,676
Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 715
[Report of cancer epidemiology in China, 2015].
Zheng, R., Sun, K., Zhang, S., Zeng, H., Zou, X., Chen, R., Gu, X., Wei, W., & He, J. (2019) · PubMed · doi:10.3760/cma.j.issn.0253-3766.2019.01.005 · Cited by 643
Self-citationNosocomial infections in patients with cancer
Kamboj, M., & Sepkowitz, K. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70069-5 · Cited by 318
Myeloid suppressor cells in cancer and autoimmunity
Sica, A., & Massarotti, M. (2017) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.07.010 · Cited by 201
Li, J.-Y., Duan, X.-F., Wang, L.-P., Xu, Y.-J., Huang, L., Zhang, T.-F., Liu, J.-Y., Li, F., Zhang, Z., Yue, D.-L., et al. (2014) · Journal of Immunology Research · doi:10.1155/2014/286170 · Cited by 157
Self-citationWang, B., Oekelen, O. V., Mouhieddine, T. H., Valle, D. M. D., Richter, J. R., Cho, H. J., Richard, S., Chari, A., Gnjatic, S., Mérad, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00934-x · Cited by 147
Cited by
Sorted by citations
Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez-Ocampo, E., Villamizar-Peña, R., Holguin-Rivera, Y., Escalera-Antezana, J. P., Alvarado-Arnez, L. E., Bonilla-Aldana, D. K., Franco-Paredes, C., Henao-Martinez, A. F., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101623 · Cited by 2,542
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020) · Viruses · doi:10.3390/v12040372 · Cited by 1,664
Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0422 · Cited by 1,589
Zhang, L., Zhu, F., Xie, L., Wang, C., Wang, J., Chen, R., Jia, P., Guan, H. Q., Li, P., Chen, Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.296 · Cited by 1,517
Self-citationLiang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
Self-citationCOVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,436
Risk factors for severe and critically ill COVID‐19 patients: A review
Gao, Y., Ding, M., Dong, X., Zhang, J., Azkur, A. K., Azkur, D., Gan, H. K., Sun, Y., Fu, W., Li, W., et al. (2020) · Allergy · doi:10.1111/all.14657 · Cited by 1,453
Self-citationHiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence
Wang, L., Wang, Y., Ye, D., & Liu, Q. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105948 · Cited by 1,234
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
Predictors of COVID ‐19 severity: A literature review
Marin, B. G., Aghagoli, G., Lavine, K., Yang, L. Z., Siff, E. J., Chiang, S. S., Salazar‐Mather, T. P., Dumenco, L. L., Savaria, M. C., Aung, S., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2146 · Cited by 857
Knowledge, Perceptions, and Attitude of Egyptians Towards the Novel Coronavirus Disease (COVID-19)
Abdelhafiz, A. S., Mohammed, Z., Ibrahim, M. E., Ziady, H. H., Alorabi, M., Ayyad, M., & Sultan, E. A. (2020) · Journal of Community Health · doi:10.1007/s10900-020-00827-7 · Cited by 856
Emami, A., Javanmardi, F., Pirbonyeh, N., & Akbari, A. (2020) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v8i1.600 · Cited by 767
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuña-Villaorduña, A., Pradhan, K., Thota, R., Reissman, S. H., Sparano, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0516 · Cited by 761
Terpos, E., Engelhardt, M. M., Cook, G., Gay, F., Mateos, M., Ntanasis‐Stathopoulos, I., van de Donk, N. W. C. J., Avet‐Loiseau, H., Hájek, R., Vangsted, A. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0876-z · Cited by 736
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
Zhang, J., Dong, X., Liu, G., & Gao, Y. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08921-5 · Cited by 782
“Many studies have demonstrated that the presence of comorbidities is more common among patients with severe COVID-19, including cardiovascular diseases [84–86], hypertension [85, 87], diabetes [84–86], COPD [85–87], malignancy [86, 87], cerebrovascular diseases [85], and chronic kidney disease [88].”
BackgroundAl-Shamsi, H. O., Alhazzani, W. A., Alhuraiji, A., Coomes, E. A., Chemaly, R. F., Almuhanna, M., Wolff, R. A., Ibrahim, N. K., Chua, M. L. K., Hotte, S. J., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0213 · Cited by 704
Coronavirus Disease 2019 (COVID-19) Pandemic
Wedri, N. M., Putra, I. P. W. N., Yasa, I. D. P., Rasdini, I. A., & Mertha, I. M. (2023) · Nursing and Health Sciences Journal (NHSJ) · doi:10.53713/nhsj.v3i2.233 · Cited by 711
Grant, M. C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L. A., Clarke, E. L., & Wade, R. G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234765 · Cited by 676
Brenner, E. J., Ungaro, R. C., Gearry, R. B., Kaplan, G. G., Kissous-Hunt, M., Lewis, J. D., Ng, S. C., Rahier, J.-F., Reinisch, W., Ruemmele, F. M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.032 · Cited by 674
Chen, R., Liang, W., Jiang, M., Guan, W., Zhan, C., Wang, T., Tang, C., Sang, L., Liu, J., Ni, Z., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.04.010 · Cited by 619
Self-citationIzcovich, A., Ragusa, M. A., Tortosa, F. G., Marzio, M. A. L., Agnoletti, C., Bengolea, A., Ceirano, A., Espinosa, F., Saavedra, E., Sanguine, V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241955 · Cited by 676
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
D’Antiga, L. (2020) · Liver Transplantation · doi:10.1002/lt.25756 · Cited by 669
Zeidan, A. M., Boddu, P. C., Patnaik, M. M., Bewersdorf, J. P., Stahl, M. F., Rampal, R. K., Shallis, R. M., Steensma, D. P., Savona, M. R., Sekeres, M. A., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30205-2 · Cited by 675
Brissot, É., Labopin, M., Baron, F., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0970-x · Cited by 660
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Pérez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M. D., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 634
Garassino, M. C., Whisenant, J. G., Huang, L., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G. L., Berardi, R., Bettini, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30314-4 · Cited by 620
Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with coronavirus disease‐19
Qu, R., Ling, Y., Zhang, Y., Wei, L., Chen, X., Li, X., Liu, X., Liu, H., Guo, Z., Ren, H., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25767 · Cited by 594
The impact of the COVID-19 pandemic on cancer care
Richards, M. A., Anderson, M., Carter, P., Ebert, B. L., & Mossialos, E. A. (2020) · Nature Cancer · doi:10.1038/s43018-020-0074-y · Cited by 587
Yang, K., Sheng, Y., Huang, C., Jin, Y., Xiong, N., Jiang, K., Lu, H., Liu, J., Yang, J., Dong, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30310-7 · Cited by 584
Self-citationLee, L. Y. W., Cazier, J., Starkey, T., Briggs, S., Arnold, R. R., Bisht, V., Booth, S. W., Campton, N. A., Cheng, V. W. T., Collins, G. P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30442-3 · Cited by 575
Clinical characteristics of 82 cases of death from COVID-19
Zhang, B., Zhou, X., Qiu, Y., Feng, F., Feng, J., Feng, J., Zhu, H., Hu, K., JiaSheng, L., Liu, Z., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235458 · Cited by 704
Wu, Y., Wang, J., Luo, C.-G., Hu, S., Lin, X., Anderson, A. E., Bruera, E., Yang, X.-X., Wei, S., & Qian, Y. (2020) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2020.04.008 · Cited by 530
Coagulopathy of Coronavirus Disease 2019
Iba, T., Levy, J. H., Levi, M. M., Connors, J. M., & Thachil, J. V. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004458 · Cited by 541
COVID-19 in Immunocompromised Hosts: What We Know So Far
Fung, M., & Babik, J. M. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa863 · Cited by 527
Passamonti, F., Cattaneo, C. M., Arcaini, L., Bruna, R., Cavo, M., Merli, F., Angelucci, E., Krampera, M., Cairoli, R., Porta, M. G. D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30251-9 · Cited by 552
Tian, J., Yuan, X., Xiao, J., Zhong, Q., Yang, C., Liu, B., Cai, Y., Lu, Z., Wang, J., Wang, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30309-0 · Cited by 526
Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C. V., Carbone, G. M., Cavalli, A., Pagano, F. C., Ragazzi, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.479 · Cited by 524
Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal
Ueda, M., Martins, R. G., Hendrie, P. C., McDonnell, T., Crews, J. R., Wong, T., McCreery, B., Jagels, B., Crane, A., Byrd, D. R., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7560 · Cited by 515
COVID-19 and Bangladesh: Challenges and How to Address Them
Anwar, S., Nasrullah, M., & Hosen, M. J. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00154 · Cited by 458
Fang, X., Shen, L., Yu, H., Wang, P., Zhang, Y., Chen, Z., Li, Y., Cheng, L., Li, W., Jia, H., et al. (2020) · Aging · doi:10.18632/aging.103579 · Cited by 492
Obesity in patients with COVID-19: a systematic review and meta-analysis
Huang, Y., Lu, Y., Huang, Y.-M., Wang, M., Ling, W., Sui, Y., & Zhao, H.-L. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154378 · Cited by 454
Jothimani, D. K., Venugopal, R., Abedin, M. F., Kaliamoorthy, I., & Rela, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.006 · Cited by 476
COVID-19 in persons with haematological cancers
He, W., Chen, L., Chen, L., Yuan, G., Fang, Y., Chen, W., Wu, D., Liang, B., Lu, X., Ma, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0836-7 · Cited by 462
Fix, O. K., Hameed, B., Fontana, R. J., Kwok, R. M., McGuire, B. M., Mulligan, D. C., Pratt, D. S., Russo, M. W., Schilsky, M. L., Verna, E. C., et al. (2020) · Hepatology · doi:10.1002/hep.31281 · Cited by 473
Risk of COVID-19 for patients with cancer
Xia, Y., Jin, R., Zhao, J., Li, W., & Shen, H. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30150-9 · Cited by 436
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
COVID-19 vaccine development: milestones, lessons and prospects
Li, M., Wang, H., Tian, L., Pang, Z., Yang, Q., Huang, T., Fan, J., Song, L., Tong, Y., & Fan, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00996-y · Cited by 478
“Antitumor treatments, including radiotherapy and chemotherapy, may lead to systemic hypoimmunity.(203) Several studies have indicated that vaccination can protect about 50–60% of cancer patients from the SARS-CoV-2 infection; thus, they should receive COVID-19 vaccines as soon as possible and complete at least two dos…”
BackgroundLai, A. G., Pasea, L., Banerjee, A., Hall, G., Denaxas, S., Chang, W. H., Katsoulis, M., Williams, B., Pillay, D., Noursadeghi, M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-043828 · Cited by 447
A War on Two Fronts: Cancer Care in the Time of COVID-19
Kutikov, A., Weinberg, D. S., Edelman, M. J., Horwitz, E. M., Uzzo, R. G., & Fisher, R. I. (2020) · Annals of Internal Medicine · doi:10.7326/m20-1133 · Cited by 426
Risk of COVID-19 for patients with cancer
Wang, H., & Zhang, L. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30149-2 · Cited by 427
Magleby, R., Westblade, L. F., Trzebucki, A. M., Simon, M. S., Rajan, M., Park, J. C., Goyal, P., Safford, M. M., & Satlin, M. J. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa851 · Cited by 429
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
Hanna, T. P., Evans, G. A., & Booth, C. M. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0362-6 · Cited by 406
Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility
Ji, H.-L., Zhao, R., Matalon, S., & Matthay, M. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00013.2020 · Cited by 412
Hilbrands, L. B., Duivenvoorden, R., Vart, P., Franssen, C. F. M., Hemmelder, M. H., Jager, K. J., Kieneker, L. M., Noordzij, M., Pena, M. J., de Vries, H., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa261 · Cited by 397
Clinical, Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-analysisPreprint
Rodriguez-Morales, A. J., Cardona-Ospina, J. A., Gutiérrez‐Ocampo, E., et al. (2020) · Preprints.org · doi:10.20944/preprints202002.0378.v1 · Cited by 411
The Impact of the COVID-19 Pandemic on Cancer Patients
Al-Quteimat, O. M., & Amer, A. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000712 · Cited by 398
Ioannou, G. N., Locke, E. R., Green, P. K., Berry, K., O’Hare, A. M., Shah, J. A., Crothers, K. A., Eastment, M. C., Dominitz, J. A., & Fan, V. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22310 · Cited by 355
Piechotta, V., Chai, K. L., Valk, S. J., Doree, C. J., Monsef, I., Wood, E. M., Lamikanra, A., Kimber, C., McQuilten, Z., So‐Osman, C., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013600.pub2 · Cited by 372
Chinese Public's Attention to the COVID-19 Epidemic on Social Media: Observational Descriptive Study
Zhao, Y., Cheng, S., Yu, X., & Xu, H. (2020) · Journal of Medical Internet Research · doi:10.2196/18825 · Cited by 366
Sharma, A., Bhatt, N. S., Martin, A. S., Abid, M. B., Bloomquist, J., Chemaly, R. F., Dandoy, C. E., Gauthier, J., Gowda, L., Perales, M., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30429-4 · Cited by 354
Caring for patients with cancer in the COVID-19 era
van de Haar, J., Hoes, L. R., Coles, C. E., Seamon, K. B., Fröhling, S., Jäger, D., Valenza, F., de Braud, F., Petris, L. D., Bergh, J. C. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0874-8 · Cited by 335
Implications of COVID-19 for patients with pre-existing digestive diseases
Mao, R., Liang, J., Shen, J., Ghosh, S. K., Zhu, L.-R., Yang, H. B., Wu, K., & Chen, M. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30076-5 · Cited by 324
Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature
Bajgain, K. T., Badal, S., Bajgain, B. B., & Santana, M. J. (2021) · American Journal of Infection Control · doi:10.1016/j.ajic.2020.06.213 · Cited by 328
Grivas, P. D., Khaki, A. R., Wise-Draper, T. M., French, B. C., Hennessy, C., Hsu, C., Shyr, Y., Li, X., Choueiri, T. K., Painter, C., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.024 · Cited by 307
COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis
Desai, A. P., Sachdeva, S., Parekh, T., & Desai, R. (2020) · JCO Global Oncology · doi:10.1200/go.20.00097 · Cited by 310
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato, A. R., Roeker, L. E., Lamanna, N., Allan, J. N., Leslie, L. A., Pagel, J. M., Patel, K., Österborg, A., Wojenski, D., Kamdar, M. K., et al. (2020) · Blood · doi:10.1182/blood.2020006965 · Cited by 303
Moletta, L., Pierobon, E. S., Capovilla, G., Costantini, M., Salvador, R., Merigliano, S., & Valmasoni, M. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.05.061 · Cited by 302
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
Curigliano, G., Banerjee, S., Cervantes, A. M. R., Garassino, M. C., Garrido, P., Girard, N., Haanen, J. B. A. G., Jordan, K., Lordick, F., Machiels, J. P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.010 · Cited by 306
Early triage of critically ill COVID-19 patients using deep learning
Liang, W., Yao, J., Chen, A., Lv, Q., Zanin, M., Liu, J., Wong, S., Li, Y., Lu, J., Liang, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17280-8 · Cited by 274
Self-citationSex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis
Abate, B. B., Kassie, A. M., Kassaw, M. W., Aragie, T. G., & Masresha, S. A. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040129 · Cited by 287
COVID-19 and comorbidities: a systematic review and meta-analysis
Gold, M. S., Sehayek, D., Gabrielli, S., Zhang, X., McCusker, C. T., & Ben‐Shoshan, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1786964 · Cited by 289
COVID-19 and Cancer: a Comprehensive Review
Gosain, R., Abdou, Y. G., Singh, A., Rana, N. K., Puzanov, I. J., & Ernstoff, M. S. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00934-7 · Cited by 295
COVID‐19 and the Otolaryngologist: Preliminary Evidence‐Based Review
Vukkadala, N., Qian, Z. J., Holsinger, F. C., Patel, Z. M., & Rosenthal, E. L. (2020) · The Laryngoscope · doi:10.1002/lary.28672 · Cited by 283
COVID-19 and Cancer: Current Challenges and Perspectives
Bakouny, Z., Hawley, J. E., Choueiri, T. K., Peters, S., Rini, B. I., Warner, J. L., & Painter, C. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.018 · Cited by 276
COVID-19 and neuromuscular disorders
Guidon, A. C., & Amato, A. A. (2020) · Neurology · doi:10.1212/wnl.0000000000009566 · Cited by 283
Kowalski, L. P., Sanabria, Á., Ridge, J. A., Ng, W. T., de Bree, R., Rinaldo, A., Takes, R. P., Mäkitie, A. A., Carvalho, A. L., Bradford, C. R., et al. (2020) · Head & Neck · doi:10.1002/hed.26164 · Cited by 289
Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors
Bargon, C. A., Batenburg, M. C. T., van Stam, L. E., van der Molen, D. R. M., van Dam, I., van der Leij, F., Baas, I. O., Ernst, M. F., Maarse, W., Vermulst, N., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa104 · Cited by 271
COVID-19 in patients with lung cancer
Luo, J. D., Rizvi, H. A., Preeshagul, I. R., Egger, J. V., Hoyos, D., Bandlamudi, C., McCarthy, C. G., Falcon, C. J., Schoenfeld, A. J., Arbour, K. C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.007 · Cited by 276
Chemotherapy and COVID-19 Outcomes in Patients With Cancer
Jee, J., Foote, M. B., Lumish, M. A., Stonestrom, A. J., Wills, B., Narendra, V. K., Avutu, V., Murciano‐Goroff, Y. R., Chan, J. E., Derkach, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01307 · Cited by 256
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
Dong, M., Zhang, J., Ma, X., Tan, J., Chen, L., Liu, S., Xin, Y., & Zhuang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110678 · Cited by 262
Challenges for NHS hospitals during covid-19 epidemic
Willan, J., King, A. J., Jeffery, K. J., & Bienz, N. (2020) · BMJ · doi:10.1136/bmj.m1117 · Cited by 251
Oncology Practice During the COVID-19 Pandemic
Schrag, D., Hershman, D. L., & Basch, E. (2020) · JAMA · doi:10.1001/jama.2020.6236 · Cited by 271
Rao, S., Lau, A., & So, H. (2020) · Diabetes Care · doi:10.2337/dc20-0643 · Cited by 277
Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review
Renu, K., Prasanna, P. L., & Gopalakrishnan, A. V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117839 · Cited by 249
Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study
Kim, D., Adeniji, N., Latt, N., Kumar, S. R., Bloom, P. P., Aby, E. S., Perumalswami, P., Roytman, M. M., Li, M., Vogel, A. S., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.09.027 · Cited by 233
Belsky, J. A., Tullius, B. P., Lamb, M. G., Sayegh, R., Stanek, J. R., & Auletta, J. J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.022 · Cited by 238
Clinical characteristics of 82 death cases with COVID-19Preprint
Zhang, B., Zhou, X., Qiu, Y., et al. (2020) · medRxiv · doi:10.1101/2020.02.26.20028191 · Cited by 249
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients
Härter, G., Spinner, C. D., Roider, J., Bickel, M., Krznaric, I., Grunwald, S., Schabaz, F., Gillor, D., Postel, N., Mueller, M. C., et al. (2020) · Infection · doi:10.1007/s15010-020-01438-z · Cited by 249
Sigel, K. M., Swartz, T. H., Golden, E., Paranjpe, I., Somani, S. S., Richter, F., Freitas, J. K. D., Miotto, R., Zhao, S., Polak, P. P., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa880 · Cited by 226
NANDY, K., Salunke, A. A., Pathak, S. K., Pandey, A. K., Doctor, C., Puj, K. S., Sharma, M. R., Jain, A., & Warikoo, V. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.064 · Cited by 226
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers
Luo, J., Rizvi, H. A., Egger, J. V., Preeshagul, I. R., Wolchok, J. D., & Hellmann, M. D. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0596 · Cited by 236
COVID-19 in cancer patients: risk, clinical features, and management
Liu, C., Zhao, Y., Okwan-Duodu, D. K., Basho, R. K., & Cui, X. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0289 · Cited by 231
Westblade, L. F., Brar, G. S., Pinheiro, L. C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J. L., Zhang, L., George, G., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.007 · Cited by 217
Curigliano, G., Cardoso, M. J., Poortmans, P. M., Gentilini, O., Pravettoni, G., Mazzocco, K., Houssami, N., Pagani, O., Senkus, E., & Cardoso, F. (2020) · The Breast · doi:10.1016/j.breast.2020.04.006 · Cited by 231
Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence
Moujaess, E., Kourié, H. R., & Ghosn, M. G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102972 · Cited by 222
Zaki, N., Alashwal, H., & Ibrahim, S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.005 · Cited by 248
Chang, A. Y., Cullen, M. R., Harrington, R. A., & Barry, M. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13184 · Cited by 221
Review article: COVID‐19 and liver disease—what we know on 1st May 2020
Garrido, I., Liberal, R., & Macedo, G. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15813 · Cited by 223
Metadata
- Authors
- Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., Li, S., & He, J.
- Affiliations
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Corresponding author
- He, Jianxing
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 21
- Issue
- 3
- Pages
- 335-337
- ISSN
- 1470-2045 (ISSN-L)
- PMC
- PMC7159000
- OpenAlex
- W3006355661
- Cited by
- 4,384
- References
- 16
- Citations by year
- 2026: 33 · 2025: 77 · 2024: 204 · 2023: 392 · 2022: 647 · 2021: 1106 · 2020: 1908
- FWCI
- 358.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- China National Science Foundation (81871893)
- Key Project of Guangzhou Scientific Research (201804020030)
- Topics
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Obstetrics and Gynecology › COVID-19 Impact on Reproduction
- Keywords
- COVID-19 pandemic, SARS-CoV-2, cancer patients, cancer survivors, COVID-19 mortality, multiple organ failure, angiotensin-converting enzyme 2, cancer care during pandemic
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Age Factors, Aged, Aged, 80 and over, China, Humans, Medical History Taking, Middle Aged, Neoplasms, Pneumonia, Viral, Prognosis, Prospective Studies, Respiration, Artificial, Risk Factors, Severity of Illness Index, Coronavirus Infections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
